ArticleFrontiers in oncology2025
Baseline PET/CT metabolic parameters in the double-expressor subtype of diffuse large B-cell lymphoma: development of a clinical-radiologic-pathologic predictive model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Double-expressor lymphoma (DEL) is an aggressive diffuse large B-cell lymphoma (DLBCL) subtype (20%-30% of cases) exhibiting resistance to standard immunochemotherapy regimens [R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)]. Multiple clinical studies have demonstrated that the combined use of new drugs such as Chidamide can significantly improve outcomes in DEL, underscoring the need for early identification of high-risk patients to guide therapy. In this context, baseline Methods: We retrospectively analyzed clinical and baseline Results: A total of 128 patients (71 men and 57 women, median age, 60 years, range, 16 to 87 years) were included in the non-DEL group ( Conclusions: TMTV, IPI, and Ki-67 are robust independent predictors of DEL. The integrated clinical-imaging-pathological prediction model constructed from these three parameters synergistically combines multi-dimensional information, significantly enhancing early DEL identification capability and facilitating the implementation of risk-adapted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.